JaLCDOI 10.18926/AMO/54815
フルテキストURL 70_6_503.pdf
著者 Kanazawa, Yui| Yamashita, Yuka| Fujiwara, Mitsuhiro| Muraoka, Michiko| Washio, Kana| Kanamitsu, Kiichiro| Ishida, Hisashi| Nakano, Takae| Yamada, Miho| Horibe, Keizo| Tanaka, Takehiro| Yoshino, Tadashi| Shimada, Akira|
抄録 Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10–30 of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60–75 disease-free survival; however, a relatively high relapse rate was observed (25–30 ). We report 2 patients with Stage III ALCL who relapsed 6–18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.
キーワード ALCL NPM-ALK fusion lymphoma
Amo Type Case Report
発行日 2016-12
出版物タイトル Acta Medica Okayama
出版者 Okayama University Medical School
開始ページ 503
終了ページ 506
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 28003677